The small compound Gleevec (Imatinib mesylate, STI571), which inhibits the tyrosine kinases c-Abl and c-Kit, is licensed for the treatment of chronic myelogenous leukemia, and blocks infections of cultured cells and mice with poxviruses, coxsackie viruses, or enteropathogenic bacteria [88],[106]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.